<DOC>
	<DOCNO>NCT00006464</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness UCN-01 cisplatin treat patient advanced metastatic solid tumor .</brief_summary>
	<brief_title>UCN-01 Cisplatin Treating Patients With Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose cisplatin administer UCN-01 patient advance solid tumor . - Assess toxicity potential antitumor activity regimen patient . - Determine pharmacokinetics regimen patient . OUTLINE : This dose-escalation , multicenter study cisplatin . Patients receive cisplatin IV 1 hour day 1 UCN-01 IV continuously 36-72 hour begin day 2 . Treatment continue every 4 week total 6 course absence disease progression unacceptable toxicity . Cohorts 1-6 patient receive escalate dos cisplatin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow every 2-3 month least 1 year . PROJECTED ACCRUAL : A total 9-30 patient accrue study within 1 year .</detailed_description>
	<mesh_term>7-hydroxystaurosporine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Staurosporine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm advanced metastatic solid tumor incurable surgery standard therapy Tumor site accessible biopsy No brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : More 3 month Hematopoietic : WBC least 4,500/mm3 Absolute neutrophil count least 2,000/mm3 Platelet count least 150,000/mm3 Hepatic : Bilirubin normal SGOT great 2.5 time upper limit normal Renal : Creatinine normal Creatinine clearance least 60 mL/min Cardiovascular : No New York Heart Association class III IV congestive heart failure Other : No peripheral neuropathy great grade I No history allergic reaction diuretic antiemetic ( e.g. , 5HT3 antagonist ) would preclude study No uncontrolled illness would preclude study , include intolerance vigorous hydration No medical , social , psychological factor would preclude study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior chemotherapy ( 6 week mitomycin nitrosoureas ) recover No great 2 prior chemotherapy regimens Prior cisplatin allow cumulative dose great 400 mg/m2 Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy recover No concurrent radiotherapy Surgery : See Disease Characteristics Recovered prior surgery Other : At least 30 day since prior investigational drug No concurrent investigational drug No concurrent anticancer agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>